Stocktoria

BGM Group Ltd. BGM

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-01-12

BGM Group Ltd. financials (annual)

Revenue
$50.0M $57.1M $64.9M $46.5M $25.1M $37.9M 202020212022202320242025
Net income
$5.1M $3.2M $1.1M -$7.8M -$1.4M -$19.9M 202020212022202320242025
Free cash flow
$4.6M -$1.1M $10.6M $132450 $304105 -$3.9M 202020212022202320242025

Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020
Revenue$37.9M$25.1M$46.5M$64.9M$57.1M$50.0M
Gross profit$6.3M$4.1M$1.8M$6.2M$5.6M$7.5M
R&D expense$672,669$1.4M$568,470$1.2M$8,000$54,000
SG&A expense$18.2M$3.3M$3.8M$4.1M$3.3M$2.7M
Operating income-$12.6M-$563,771-$2.6M$2.1M$2.4M$4.8M
Interest expense$57,671$242,877
Income tax$277,790-$619,981$219,166$194,302$255,133$864,908
Net income-$19.9M-$1.4M-$7.8M$1.1M$3.2M$5.1M
EPS (diluted)$-0.18$-0.20$-1.08$0.15$0.09$0.17
Operating cash flow-$2.4M$544,238$312,209$12.7M$345,034$5.1M
Free cash flow-$3.9M$304,105$132,450$10.6M-$1.1M$4.6M
Cash & equivalents$9.8M$9.8M$7.5M$14.3M$10.5M$11.9M
Inventory$20.1M$5.0M$5.0M$8.9M$12.5M$12.0M
Total assets$433.8M$53.0M$51.3M$64.5M$75.4M$48.1M
Total liabilities$41.9M$8.9M$6.9M$9.6M$18.7M$19.3M
Shareholders' equity$391.9M$44.1M$44.4M$55.0M$56.7M$28.8M

Growth · year-over-year · Revenue CAGR -5.4%

MetricFY2025FY2024FY2023FY2022FY2021FY2020
Revenue growth+51.1%-46.0%-28.3%+13.6%+14.1%
Net income growth-822.6%-65.9%-37.7%
EPS growth-820.0%+66.7%-47.1%
Free cash flow growth-1395.3%+129.6%-98.8%-124.8%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2024-09-30. Facts plus Stocktoria's own computed scores — not investment advice.